Business By Kate Sheridan Prescription apps are gaining ground — and drug makers’ backing — as digital therapeutics
Pharmalot By Ed Silverman What clinical trial results? Now you can see who isn’t sharing their findings
Business By Rebecca Robbins The insulin market is heading for a shakeup. But patients may not benefit
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Conservative group runs ads to defeat Medicare Part B overhaul
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Sanofi threatens to launch a hostile bid for Medivation
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Medivation rejects Sanofi’s $9.3 billion bid as ‘undervalued’
Pharmalot By Ed Silverman A frustrated Sanofi makes $9.3 billion bid for Medivation and its cancer drug
Health By Helen Branswell Sanofi science chief says it’s time to ‘think big’ about global epidemics like Zika
Pharmalot By Ed Silverman Pharmalot, Pharmalittle: Some investors losing confidence in Valeant, Sanofi abandoning allergy med
Business By Karen Weintraub From the ivory tower to the corner office, academics infuse new life into pharma